← brief for 2026-11-15 · Slowing decline
ADVANCES IN NEPHROPROTECTIVE THERAPY IN CHRONIC KIDNEY DISEASE: THE ROLE OF SGLT2 INHIBITORS AND FINERENONE
Key takeaways
This review summarizes large trials showing that SGLT2 inhibitors and finerenone protect the kidneys. These drugs slow kidney decline and lower heart risks. The evidence is strong because it comes from big, well-run studies.
Who did this work
Xakimova I.T. (Andijan State Medical Institute) · Worldly Knowledge Publishing Centre
Source
Article · OpenAlex, Kidney disease concept sweep (verified C2778653478) · 2026-11-14
https://doi.org/10.5281/zenodo.24218624